Indication

In combination with a hypomethylating agent (HMA) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy (IC).

Medicine details

Medicine name:
venetoclax (Venclyxto)
SMC ID:
SMC2412
Pharmaceutical company
AbbVie Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
11 April 2022
SMC meeting date:
01 March 2022
Patient group submission deadline:
13 December 2021